Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis: a case series

This article was originally published here

Adv Respir Med. 2021;89(6):589-596. doi: 10.5603/ARM.a2021.0113.


The current COVID-19 pandemic has spread like wildfire worldwide and has affected millions of people. The novel corona virus mainly affects the lungs leading to life threatening disease like acute respiratory distress syndrome (ARDS). The aftermath of the disease in form of pulmonary fibrosis is upcoming cause of further increase in morbidity and mortality. Nintedanib is an oral antifibrotics with proven role in idiopathic pulmonary fibrosis, however its use in COVID-19 related pulmonary fibrosis has not been studied. We report our early experience of use of nintedanib in COVID-19 related pulmonary fibrosis.

PMID:34966994 | DOI:10.5603/ARM.a2021.0113